Critical Care Medicine
Gastrointestinal Emergencies: Hirschsprung Disease, Congenital Aganglionic Megacolon
Also known as: Congenital Aganglionic Megacolon
1. Description of the problem
Hirschsprung disease (HD) describes a failure of neural crest cell migration to the entire colon during intestinal development. The result is an aganglionic segment of colon that is unable to relax, causing obstruction and the potential for severe complications.
Delay/failure of passage of stools (including meconium)
Chronic constipation in children/adults with low-segment HD.
Rectal biopsy - The gold standard of HD diagnosis is a rectal biopsy, with absent ganglion cells often confirmed by elevated acetylcholinesterase activity in special staining and hypertrophic nerve fibers. Rectal suction biopsy are often sufficient and can be done without general anesthesia. If nondiagnostic, a full-thickness biopsy may be necessary.
Abdominal X-ray - A distal intestinal obstruction with dilated bowel loops often suggests HD and identifies the likely transition zone
Contrast enema - A sharp transition zone often in the recto-sigmoid colon suggests the diagnosis of HD and can help surgeons locate the transition point or suggest the need for a rectal suction biopsy to confirm HD.
Anorectal manometry - especially useful for short-segment HD with the inability to relax the internal anal sphincter with balloon distention of the rectum. If the internal anal sphincter relaxes with balloon distention, HD is excluded.
4. Specific Treatment
Treatment of HD is surgical. If emergent, a colostomy is often necessary prior to a second-stage pull-through. If non-emergent, a one-stage pull-through is possible without a significant increase in the complication rate.
The prognosis or HD after pull-through is excellent, with near-normal anorectal function unless total colonic aganglionosis is present. Fecal incontinence and chronic constipation are the most common long-term complications.
Copyright © 2017, 2013 Decision Support in Medicine, LLC. All rights reserved.
No sponsor or advertiser has participated in, approved or paid for the content provided by Decision Support in Medicine LLC. The Licensed Content is the property of and copyrighted by DSM.
Sign Up for Free e-newsletters
- Hodgkin Lymphoma Survivorship Marked by Periods of Actionable Distress
- Dose-Escalation Mitigates Risk of Grade 3/4 Adverse Events With Ruxolitinib for Myelofibrosis
- Stem Cell Transplantation Superior to Chemotherapy for Relapsed/Refractory DLBCL, Follicular Lymphoma
- Patients and Caregivers Worry About Cost of Cancer Care
- Open Hysterectomy Survival Rates Edge Minimally Invasive Procedures for Cervical Cancer
- Navigating Prostate Cancer: A Patient's Experience From Diagnosis to Survivor
- Cell Phones and Cancer Risk (Fact Sheet)
- How Likely Are Oncologists to Refer for Palliative Care? Depends on Their Age
- Use of Corticosteroids With PD-1 or PD-L1 Inhibitors Associated With Poorer Outcomes in NSCLC
- Chemoimmunotherapy Increases Survival in Triple-Negative Breast Cancer
- Risk for Colon Cancer, Osteogenic Sarcoma Higher With Presence of Diamond-Blackfan Anemia
- G-CSF Support Increases Overall Survival, But Risk of Secondary Malignancies Also Higher
- Report From Childhood Cancer Survivor Study Identifies Long-Term Risks for VTE
- The Effect of Intravenous Hydration Strategy on Plasma Methotrexate Clearance During Intravenous High-dose Methotrexate Administration in Pediatric Oncology Patients
- Outcomes Worse for Minimally Invasive Hysterectomy vs Open Surgery
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|